CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal cancers.
  
  OVERVIEW OF ACTIVITY
  Cancer of the colon or rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States. In the year 2019, it is estimated that 145,600 people will be diagnosed with colon or rectal cancer in the United States, representing a continued decline over the past few decades thought to be related to improvements in detection and treatment.
  
  Published results from ongoing trials continually lead to the emergence of new therapeutic targets and regimens, thereby altering management algorithms, and in order to offer optimal patient care, including the option of clinical trial participation, the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, this issue of Oncology Today with Dr Neil Love — Gastrointestinal Cancers Edition, which focuses on advanced colorectal cancer (CRC), features a joint discussion with 2 leading gastrointestinal oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.
  
  LEARNING OBJECTIVES

  • Recall recent pivotal research results specific to the systemic management of advanced CRC as published in peer-reviewed journals and/or presented at major oncology conferences.
  • Consider patient and disease characteristics in selecting therapy for patients with metastatic CRC (mCRC), including primary tumor location and presence of potentially targetable genetic abnormalities (eg, RAS, BRAF, HER2).
  • Appraise the rationale for and clinical data with commercially available and investigational immune checkpoint inhibitors for patients with microsatellite instability-high or mismatch repair-deficient mCRC.
  • Develop a long-term care plan for patients with mCRC with BRAF V600E tumor mutations.
  • Devise a rational approach to the incorporation of regorafenib and TAS-102 into the treatment algorithm for mCRC that includes consideration of each agent’s unique side-effect profile.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THESE CME ACTIVITIES
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Professor Dirk Arnold, MD, PhD
  Director
  Asklepios Tumorzentrum Hamburg
  Chair
  Department of Oncology and Hematology
  Asklepios Klinik Altona
  Hamburg, Germany
  
  No relevant conflicts of interest to disclose.
  
  Johanna Bendell, MD
  Chief Development Officer
  Director, Drug Development Unit Nashville
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Advisory Committee, Consulting Agreements and Contracted Research: Abbott Laboratories, AbbVie Inc, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Cyteir Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics, Eisai Inc, EMD Serono Inc, Evelo Biosciences, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, Gilead Sciences Inc, GlaxoSmithKline, Gritstone Oncology, Harpoon Therapeutics, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Janssen Biotech Inc, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MedImmune Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Molecular Partners, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, PhoenixBio, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Sierra Oncology, Sorrento Therapeutics, Stemcentrx, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, TG Therapeutics Inc, Tizona Therapeutics Inc, TORQUE Pharmaceuticals, TRACON Pharmaceuticals, Tyrogenex Inc, Unum Therapeutics Inc, Vyriad; Data and Safety Monitoring Board: Acceleron Pharma, Five Prime Therapeutics Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Lilly.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: February 2019
  Expiration date: February 2020